AUTHORS
David Ciemnecki, Taylor Bowles2, Caroline Kruse, BA3, James Bussel, MD4
AFFILIATIONS
1 Platelet Disorder Support Association, Cleveland, Ohio, United States
2 OU Hudson College of Public Health, Oklahoma City, Oklahoma, United States, Platelet Disorder Support Association, Cleveland, Ohio, United States
3 Platelet Disorder Support Association, Cleveland, Ohio, United States
4 Weill Cornell Medical College, New York, New York, United States
ABSTRACT
Introduction:
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by thrombocytopenia, bruising, petechiae, mucosal bleeding, and, in severe cases, intracranial hemorrhage. The clinical course of ITP is highly variable, with platelet counts and bleeding manifestations changing over time. Although platelet counts are routinely monitored in ITP, longitudinal platelet count trajectories are less well studied. Platelet trajectories may provide additional insight into ITP (Provan et al., 2019) but their relationship with patient-reported bleeding remains unstudied.
Aims:
To characterize platelet count trajectories in the PDSA ITP Natural History Study Registry and evaluate their relationship with bleeding events, bruising trajectories, and treatment exposure.
Methods:
The ITP registry included 388 participants completing the Bleeding and Hospitalization survey, reporting platelet counts and bleeding across time intervals since diagnosis (0-3 months through >10 years). Platelet count trajectories were classified as improved, stable, or worsened based on whether the most recent reported platelet count was higher than, unchanged from, or lower than the baseline (0-3 months) category. Bruising trajectories were categorized as never, resolved, persistent, or late-onset, based on symptom reports during the early (<1 year) and chronic (≥1 year) phases. Bleeding was categorized as any reported bleeding event after baseline (yes/no). Associations between platelet trajectories and bruising and bleeding outcomes were evaluated using Pearson’s chi-square test. Treatment exposure was also evaluated, including first-line (such as steroids and IVIG), targeted (TPO-RA, rituximab), and immunosuppressive therapies, and treatment burden (i.e., number of treatments).
Results:
Among registry participants with baseline and follow-up platelet count data (n=295), most demonstrated improved platelet count trajectories over time (67%, 198/295), while smaller proportions remained stable (20%, 60/295) or worsened (13%, 37/295). Among participants with bruising data (n=259), persistent bruising trajectories were seen in 62% (160/259), while 38% (99/259) had non-persistent bruising patterns (never, resolved, or late-onset bruising). Bruising pattern (persistent vs. non-persistent) was significantly associated with platelet trajectory group (p=0.018), with persistent bruising more frequently reported among participants with improved platelet trajectories. Non-persistent bruising patterns were seen in 61% (19/31) of participants with worsened trajectories, 37% (18/48) with stable trajectories and 34% (62/180) with improved trajectories. Conversely, persistent bruising was seen in 39% (12/31), 63% (30/48), and 66% (118/180) of participants with worsened, stable, and improved platelet trajectories, respectively.
Subsequent bleeding events were reported by 32% (95/295) of participants. Bleeding was not significantly associated with platelet trajectory group (p=0.353), occurring in 33% (66/198) of participants with improved platelet trajectories, 25% (15/60) with stable trajectories, and 38% (14/37) with worsened trajectories.
Treatment exposure categories were not significantly associated with platelet trajectory (all p>0.05). Improved platelet trajectories were observed among 70% (49/70) of participants receiving first-line therapies only, 72% (94/130) receiving ITP-targeted therapies, and 56% (9/16) receiving immunosuppressive therapies. Treatment burden (number of treatments) also did not demonstrate consistent associations with platelet trajectory.
Conclusion:
Platelet trajectories improved for most participants. Surprisingly, although platelet trajectory improved, this was NOT associated with reduced subsequent bleeding events. Rather, participants with improved platelet trajectories more commonly reported persistent bruising, whereas those with stable or worsened trajectories more frequently reported non-persistent bruising patterns. This discordance between bruising and bleeding outcomes in relation to platelet trajectories warrants further investigation to confirm these findings and identify potential explanations. Possible explanations for the unexpected association between bruising and platelet trajectories include that individuals with improved platelet counts may either be more active or may be more comfortable using medications such as NSAIDs (e.g. ibuprofen), both of which may contribute to bruising.
DISCLOSURES
David Ciemnecki: No relevant conflicts of interest to declare.